Sleep appears within UCLA Health’s comprehensive menopause assessment, alongside other health concerns. That breadth is useful, but it does not identify a medicine for every person who reports poor sleep. It also does not turn a capsule’s potential to cause drowsiness into evidence that the capsule treats the underlying concern.
Reviewed September 29, 2026, UCLA provides an actual menopause clinical service and publishes concrete preparation information. Its reviewed pages do not confirm an oral progesterone product. This assessment separates the program’s scope from a named medicine’s role, ingredients and cautions.
In this article
The program starts with a broad health picture
UCLA’s clinical services page describes an individualized menopause plan involving several areas of health, including sleep, mood, cardiovascular concerns, bone health and genitourinary symptoms. It also identifies specialist involvement when relevant. The page supports a comprehensive clinical service; it does not establish that one medicine addresses every part of that service.
The Northwestern review examines another program with multiple approaches. In both cases, the range of topics is a description of assessment capacity. It should not be converted into a list of benefits attributed to oral progesterone, a promise of symptom relief, or a reason to assume a particular prescription will follow the appointment.
The questionnaire prepares a conversation
UCLA asks patients to complete a substantial health questionnaire before the visit. Its patient information estimates that the questionnaire can take 30 to 45 minutes and requests it at least seven days before the appointment. Those are the program’s administrative instructions, not a medicine schedule or a test that determines progesterone suitability.
The useful point is that the service seeks a fuller history before making an individual plan. A sleep concern may be one part of that history without defining the entire consultation. Completing the form does not confirm a prescription, a particular formulation or a diagnosis. The reviewed page does not provide a self-scoring rule for deciding whether a capsule is appropriate.
Distinguish the desired outcome from an unwanted effect
Prometrium’s patient information warns about dizziness and drowsiness and cautions about activities that can be affected. The label does not make the occurrence of those effects proof that a patient’s sleep concern is being treated successfully. A potential adverse effect and the reason for prescribing are different parts of the medicine discussion.
The drowsiness questions guide explores that distinction without proposing a dose or schedule. If an oral medicine is discussed, the clinician would need to explain the intended role and the plan for concerns. UCLA’s inclusion of sleep in comprehensive care cannot supply that product-specific explanation, and this review does not infer a sleep indication from it.
The exact medicine matters even within hormone therapy
The Prometrium label identifies oral progesterone and describes defined uses, including a role alongside estrogen after menopause under specified circumstances. UCLA’s service overview does not name that product as the program’s routine prescription. A broad hormone-care description cannot establish an oral route, manufacturer or pharmacy.
The purpose guide places the reason for a medicine ahead of assumptions about its name. The Stanford review provides a comparison with a treatment page that more explicitly explains progesterone’s accompanying role. Even that additional detail does not identify a capsule for an individual patient. Service descriptions and product records answer different questions.
Allergy information requires a formulation record
Prometrium’s documented ingredients include peanut oil, and the label includes a peanut-allergy contraindication. Those are exact product facts. They do not prove that a UCLA patient would receive that medicine or that all progesterone capsules have the same formulation. The current label is useful precisely because it is specific rather than generic.
The excipient guide explains why a conversation about allergy history needs to connect to the actual dispensed product. The treating clinician and pharmacist have different contributions to that assessment. A broad clinic questionnaire may gather relevant history, but its completion is not evidence that an unidentified capsule has been checked or that a contraindication has been resolved.
A yearly review is not a universal medicine timetable
UCLA’s patient page describes follow-up as needed and a yearly comprehensive assessment. That is the program’s general care structure. It is not a published promise that a particular prescription lasts a year, or a rule that medicine-related questions should wait until the annual visit. The patient information does not set an oral progesterone refill or monitoring schedule.
Our follow-up guide separates routine appointments from responsibility for concerns that arise between them. The useful unresolved details include which team receives a question, who reviews the actual medicine plan and what follow-up the treating professional considers appropriate. This review does not replace those decisions with a calendar derived from a general program description.
The service is clearer than the purchase terms
UCLA’s reviewed pages explain care and preparation more fully than they explain prescription purchasing. They do not establish a complete oral progesterone price, a supplied capsule, included dispensing or individual insurance coverage. The clinical overview therefore supports assessment of a care pathway, not comparison of a fixed medicine package.
A reader can compare the breadth of the consultation and the published preparation requirements while keeping financial and formulation questions open. A proposed plan would still need to distinguish its purpose, expected follow-up and exact medicine information. Neither the university affiliation nor a comprehensive list of health topics demonstrates a superior capsule, a personal outcome or freedom from the warnings of the product ultimately prescribed.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- UCLA Health — Comprehensive Menopause Program: Clinical ServicesOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- UCLA Health — Comprehensive Menopause Program: Patient InformationOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- DailyMed — Prometrium progesterone capsule, Acertis Pharmaceuticals LLCCurrent exact oral Prometrium DailyMed label, updated July 23, 2026; patient leaflet revision February 2026. Does not establish provider supply. · Checked 2026-09-29